Can HPV vaccine have other health benefits more than cancer prevention? A systematic review of association between cervical HPV infection and preterm birth

Journal of Clinical Virology

Volumn 61, Issue 3, 2014, Pages 321-328

  Huang, Qi tao ^a,b   Zhong, Mei ^a   Gao, Yun fei ^a   Huang, Li ping ^a   Huang, Qiong ^a   Wang, Wei ^a   Wang, Zhi jian ^a   Yu, Yan hong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cervix; Human papillomavirus; Preterm birth

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

CANCER PREVENTION; CASE CONTROL STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; META ANALYSIS; PAPILLOMAVIRUS INFECTION; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS; COMPLICATION; FEMALE; INSURANCE; PAPILLOMAVIRUS INFECTIONS; PREMATURE BIRTH; UTERINE CERVICAL NEOPLASMS;

FEMALE; HUMANS; INSURANCE BENEFITS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREMATURE BIRTH; UTERINE CERVICAL NEOPLASMS;

EID: 84908567112     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.09.002     Document Type: Review

References (49)

1. Liu B., Taioli E. Associations between human papillomavirus and history of cancer among U.S. adults in the National Health and Nutrition Examination Survey (2003-2010). Br J Cancer 2014, (July). [Epub ahead of print]. 10.1038/bjc.2014.414.
2. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297(February (8)):813-819.
3. Rositch A.F., Soeters H.M., Offutt-Powell T.N., Wheeler B.S., Taylor S.M., Smith J.S. The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. Gynecol Oncol 2014, 132(March (3)):767-779.
4. Moscicki A.B., Schiffman M., Burchell A., Albero G., Giuliano A.R., Goodman M.T., et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012, 30(November (Suppl. 5)):F24-F33.
5. Hopkins T.G., Wood N. Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine 2013, 31(March (13)):1673-1679.
6. Jenson H.B. Human papillomavirus vaccine: a paradigm shift for pediatricians. Curr Opin Pediatr 2009, 21(February (1)):112-121.
7. Kjellberg L., Hallmans G., Ahren A.M., Johansson R., Bergman F., Wadell G., et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000, 82(April (7)):1332-1338.
8. Liu P., Xu L., Sun Y., Wang Z. The prevalence and risk of human papillomavirus infection in pregnant women. Epidemiol Infect 2014, 142(August (8)):1567-1578.
9. Blencowe H., Cousens S., Oestergaard M.Z., Chou D., Moller A.B., Narwal R., et al. National, regional, and worldwide estimates of PTB rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012, 379(June (9832)):2162-2172.
10. Morken N.H. PTB: new data on a global health priority. Lancet 2012, 379(June (9832)):2128-2130.
11. Damus K. Prevention of PTB: a renewed national priority. Curr Opin Obstet Gynecol 2008, 20(December (6)):590-596.
12. Hong J.N., Berggren E.K., Campbell S.L., Smith J.S., Rahangdale L. Abnormal cervical cancer screening in pregnancy and preterm delivery. Paediatr Perinat Epidemiol 2014, 28(July (4)):297-301.
13. Zuo Z., Goel S., Carter J.E. Association of cervical cytology and HPV DNA status during pregnancy with placental abnormalities and PTB. Am J Clin Pathol 2011, 136(August (2)):260-265.
14. He Y., Wu Y.M., Wang T., Song F., Wang Y., Zhu L. Perinatal outcomes of pregnant women with cervical intraepithelial neoplasia. Arch Gynecol Obstet 2013, 288(December (6)):1237-1242.
15. Skoczyński M., Goździcka-Józefiak A., Kwaśniewska A. Prevalence of human papillomavirus in spontaneously aborted products of conception. Acta Obstet Gynecol Scand 2011, 90(December (12)):1402-1405.
16. Sifakis S., Ergazaki M., Sourvinos G., Koffa M., Koumantakis E., Spandidos D.A. Evaluation of Parvo B19, CMV and HPV viruses in human aborted material using the polymerase chain reaction technique. Eur J Obstet Gynecol Reprod Biol 1998, 76(February (2)):169-173.
17. Cho G., Min K.J., Hong H.R., Kim S., Hong J.H., Lee J.K., et al. High-risk human papillomavirus infection is associated with premature rupture of membranes. BMC Pregnancy Childbirth 2013, 13(September):173.
18. McDonnold M., Dunn H., Hester A., Pacheco L.D., Hankins G.D., Saade G.R., et al. High risk human papillomavirus at entry to prenatal care and risk of preeclampsia. Am J Obstet Gynecol 2014, 210(February (2)):e1381-e1390.
19. Sjøborg K.D., Eskild A. Vaccination against human papillomavirus - an impact on preterm delivery? Estimations based on literature review. Acta Obstet Gynecol Scand 2009, 88(3):255-260.
20. Gomez L.M., Ma Y., Ho C., McGrath C.M., Nelson D.B., Parry S. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. Hum Reprod 2008, 23(March (3)):709-715.
21. Comar M., Monasta L., Zanotta N., Vecchi Brumatti L., Ricci G., Zauli G. Human papillomavirus infection is associated with decreased levels of GM-CSF in cervico-vaginal fluid of infected women. J Clin Virol 2013, 58(October (2)):479-481.
22. Yang R., Wang Y., Qiao J., Liu P., Geng L., Guo Y.L. Does human papillomavirus infection do harm to in-vitro fertilization outcomes and subsequent pregnancy outcomes?. Chin Med J (Engl) 2013, 126(February (4)):683-687.
23. Rositch A.F., Koshiol J., Hudgens M.G., Razzaghi H., Backes D.M., Pimenta J.M., et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer 2013, 133(September (6)):1271-1285.
24. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151(4):W65-W94.
25. Wells G., Shea B.O., Connell D. The Newcastle-Ottawa Scale (Nos) for assessing the quality of nonrandomized studies in meta-analysis 2010, http://www.ohri.ca/programs/clinical_epidemiology/oxford_web.ppt.
26. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
27. Egger M., Smith G.D. Bias in location and selection of studies. BMJ 1998, 316(7124):61-66.
28. Jones R. Crohn's disease and PTB. Nat Rev Gastroenterol Hepatol 2010, 7(August (8)):416.
29. Ma K.K., Nelson J.L., Guthrie K.A., Dugowson C.E., Gammill H.S. Adverse pregnancy outcomes and risk of subsequent rheumatoid arthritis. Arthritis Rheumatol 2014, 66(March (3)):508-512.
30. Mbulaiteye S.M., Kemp T., Gage J.C., Ajenifuja K.O., Kiruthu C., Wentzensen N.A., et al. Plasma cytokine levels and human papillomavirus infection at the cervix in rural Nigerian women. Cytokine 2013, 64(October (1)):146-151.
31. Scott M.E., Shvetsov Y.B., Thompson P.J., Hernandez B.Y., Zhu X., Wilkens L.R., et al. Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. Int J Cancer 2013, 133(September (5)):1187-1196.
32. Ali K.S., Ali H.Y., Jubrael J.M. Concentration levels of IL-10 and TNFα cytokines in patients with human papilloma virus (HPV) DNA(+) and DNA(-) cervical lesions. J Immunotoxicol 2012, 9(April-June (2)):168-172.
33. Hong J.H., Kim M.K., Lee I.H., Kim T.J., Kwak S.H., Song S.H., et al. Association between serum cytokine profiles and clearance or persistence of high-risk human papillomavirus infection: a prospective study. Int J Gynecol Cancer 2010, 20(August (6)):1011-1016.
34. Sharma A., Rajappa M., Saxena A., Sharma M. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer 2007, 17(July-August (4)):879-885.
35. Alcocer-González J.M., Berumen J., Taméz-Guerra R., Bermúdez-Morales V., Peralta-Zaragoza O., Hernández-Pando R., et al. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 2006, 19(Summer (3)):481-491.
36. Racicot K., Cardenas I., Wünsche V., Aldo P., Guller S., Means R.E., et al. Viral infection of the pregnant cervix predisposes to ascending bacterial infection. J Immunol 2013, 191(July (2)):934-941.
37. Gillet E., Meys J.F., Verstraelen H., Bosire C., De Sutter P., Temmerman M., et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. BMC Infect Dis 2011, 11(January):10.
38. Dodd J.M., McLeod A., Windrim R.C., Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2013, 7(July):CD006780.
39. Kovo M., Schreiber L., Bar J. Placental vascular pathology as a mechanism of disease in pregnancy complications. Thromb Res 2013, 131(January (Suppl. 1)):S18-S21. 10.1016/S0049-3848(13)70013-6.
40. Cha J., Sun X., Dey S.K. Mechanisms of implantation: strategies for successful pregnancy. Nat Med 2012, 18(December (12)):1754-1767.
41. Hermonat P.L., Kechelava S., Lowery C.L., Korourian S. Trophoblasts are the preferential target for human papilloma virus infection in spontaneously aborted products of conception. Hum Pathol 1998, 29(February (2)):170-174.
42. You H., Liu Y., Carey M.J., Lowery C.L., Hermonat P.L. Defective 3A trophoblast-endometrial cell adhesion and altered 3A growth and survival by human papillomavirus type 16 oncogenes. Mol Cancer Res 2002, 1(November (1)):25-31.
43. Simhan H.N., Bodnar L.M. Prepregnancy body mass index, vaginal inflammation, and the racial disparity in PTB. Am J Epidemiol 2006, 163(March (5)):459-466.
44. Culhane J.F., Goldenberg R.L. Racial disparities in PTB. Semin Perinatol 2011, 35(August (4)):234-239.
45. Koh W.J., Greer B.E., Abu-Rustum N.R., Apte S.M., Campos S.M., Chan J., et al. National comprehensive cancer network. Cervical cancer. J Natl Compr Cancer Netw 2013, 11(March (3)):320-343.
46. Conner S.N., Frey H.A., Cahill A.G., Macones G.A., Colditz G.A., Tuuli M.G. Loop electrosurgical excision procedure and risk of preterm birth: a systematic review and meta-analysis. Obstet Gynecol 2014, 123(April (4)):752-761.
47. Torres A., Rosa E.R., Méndez K., Menéndez A., Romaguera J. Cervical dysplasia and pre-term birth in San Juan city hospital: a cohort retrospective study. Bol Asoc Med P R 2013, 105(2):36-38.
48. Tshomo U., Franceschi S., Dorji D., Baussano I., Tenet V., Snijders P.J., et al. Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme. BMC Infect Dis 2014, 14(July (1)):408.
49. Kwon J.Y., Romero R., Mor G. New insights into the relationship between viral infection and pregnancy complications. Am J Reprod Immunol 2014, 71(May (5)):387-390.